Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIACI of Cetuximab and Bevacizumab in Pediatric Relapsed/Refractory Intracranial Glioma
NCT05956821Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Jun 2025
- Primary completion
- Oct 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and bevacizumab in glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), Fibrillary astrocytoma (DA) and 2 more, sponsored by University of Miami. Primary endpoints: Number of Treatment Related Adverse Events, Composite Overall Response Rate at 6 months and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
cetuximabbevacizumab
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)Fibrillary astrocytoma (DA)Oligodendroglioma (OG)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT05956821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05956821.